(Speedwell Members click here for an extended version of this post or here for a PDF)
3Q25 Update.
Axon reported 3Q25 earnings Tuesday and the stock closed -9% after initially dropping -20%. It faced continued pressure though and is now down -16% at $600 from its pre-earnings price of $720.
This quarter marked the 15th consecutive quarter of 25%+ growth and the 7th quarter of 30%+ growth. Total revenue rose +31% y/y to $711mn, a slight deceleration from +33% y/y in the prior quarter. Net revenue retention remained robust at 124%, consistent with last quarter and marking the company’s 21st consecutive quarter over 120%.
Breaking down their $711mn total revenue by segment, Software & Service Segment accelerated again to +41% y/y, a 200 bps increase from last quarter’s growth rate of +39%, driven by adoption of premium software features and an expanding user base. However, the Connected Devices segment slowed, growing +24% y/y to $405mn, a -500bps contraction from the prior quarter. Within the segment, TASER revenues grew +17%, Personal Sensors rose +20%, and Platform Solutions increased +71%. Each category saw a slight contraction in growth from the prior quarter, but growth remained steady.
With continued success they are seeing across their ecosystem, they’re raising their revenue guidance for the remaining of the year. They expect 4Q revenue between $750-$755mn, and full year revenue of $2.74bn up from $2.65-2.73bn, representing an annual revenue growth rate of ~31%.
Turning to profitability, total gross margins held steady at 60%. Product gross margins improved +100 basis points to 50%, however offsetting this was Software & Services margins contracting -200bps to 74% from 76%. CFO Brittany Bagley noted that this was the first full quarter to feel the effect of tariffs, primarily in the Connected Devices segment, though production shifts to India and Vietnam helped offset some of the pressure.
Axon continues to increase their R&D spend as they build out the TASER 10 and innovate new product offerings. In the quarter, R&D rose +54% y/y, but despite this increase, R&D is still running at 24% of revenues.
Despite strong revenue growth, their elevated operating expenses, high SBC, and slow cash conversion cycle means that revenues haven’t been converting to cash. After backing out SBC, they burned $113mn in 3Q.
Business Commentary.
A major focus of the quarter was Axon’s expansion into…
The rest of this update is only accessible to Speedwell Members.
If you are a Speedwell Member, click here to read the rest of this post.
If you are not currently a Speedwell Member, but wish to join, click here.
Members also get acces to our full 75 page Axon Research Report, on-going updates, and are large library of other reports.
For further reading, check out our Axon Extensive Research Report.
The Synopsis Podcast.
Follow our Podcast below. We have four episode formats: “company” episodes that breakdown in-depth each business we write a report on, “dialogue” episodes that cover various business and investing topics, “article” episodes where we read our weekly memos, and “interviews”.
Speedwell Research Reports.
Become a Speedwell Research Member to receive all of our in-depth research reports, shorter exploratory reports, updates, and Plus members also receive Excels.
(Many members have gotten their memberships expensed. If you need us to talk with your compliance department to become an approved vendor, please reach out at info@speedwellresearch.com).
*At the time of this writing, one or more contributors to this report has a position in Axon. Furthermore, accounts one or more contributors advise on may also have a position in Axon. This may change without notice.
Leave a Reply